MexicoTuberculosis profile
Population  2015 127 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.6 (2.6–2.7) 2.1 (2–2.1)
Mortality (HIV+TB only) 0.51 (0.03–1.7) 0.4 (0.02–1.3)
Incidence  (includes HIV+TB) 27 (22–32) 21 (17–25)
Incidence (HIV+TB only) 3 (1.9–4.3) 2.3 (1.5–3.4)
Incidence (MDR/RR-TB)** 0.91 (0.75–1.1) 0.72 (0.59–0.87)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 1.2 (0.64–1.7) 9 (6–12) 10 (6.6–14)
Males 1.3 (0.84–1.7) 15 (12–18) 16 (12–20)
Total 2.4 (1.8–3.1) 24 (21–27) 27 (22–32)
TB case notifications, 2015  
Total cases notified 22 294
Total new and relapse 21 600
          - % tested with rapid diagnostics at time of diagnosis 1%
          - % with known HIV status 89%
          - % pulmonary 81%
          - % bacteriologically confirmed among pulmonary 83%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 81% (68–99)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.12 (0.08–0.16)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 2 188 11%
          - on antiretroviral therapy 2 120 97%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  610
(540–670)
Estimated % of TB cases with MDR/RR-TB 2.6% (2.3–2.9) 11% (9.2–13)  
% notified tested for rifampicin resistance 2% 35% 1 072
MDR/RR-TB cases tested for resistance to second-line drugs   51
Laboratory-confirmed cases MDR/RR-TB: 158, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 146, XDR-TB: 5
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 80% 21 193
Previously treated cases, excluding relapse, registered in 2014 53% 685
HIV-positive TB cases, all types, registered in 2014 48% 1 318
MDR/RR-TB cases started on second-line treatment in 2013 60% 167
XDR-TB cases started on second-line treatment in 2013 75% 4
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 19%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) 19
Funding source: 100% domestic, 0% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data